We are live on ! Find out more
TCM

Tang Capital Management Portfolio holdings

AUM $1.97B
1-Year Est. Return 125.1%
This Fund
S&P 500
This Quarter Est. Return
+16.47%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$1.4B
AUM Growth
+$418M
Cap. Flow
+$336M
Cap. Flow %
23.99%
Top 10 Hldgs %
35.88%
Holding
162
New
35
Increased
43
Reduced
14
Closed
8

Top Buys

Rank Stock Value
1
ITOS
iTeos Therapeutics
ITOS
+$36.7M
2
CRBP icon
Corbus Pharmaceuticals
CRBP
+$30.7M
3
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$27.6M
4
RLAY icon
Relay Therapeutics
RLAY
+$26.7M
5
IMCR icon
Immunocore
IMCR
+$25.5M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$24.4M
2
DVAX
Dynavax Technologies
DVAX
+$6.61M
3
BEAM icon
Beam Therapeutics
BEAM
+$2.58M
4
CRSP icon
CRISPR Therapeutics
CRSP
+$2.54M
5
INBX icon
Inhibrx
INBX
+$2.37M

Sector Composition

Rank Sector Weight
1 Healthcare 95.59%
2 Technology 1.47%
3 Communication Services 1.22%
4 Real Estate 0.34%
5 Financials 0.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCAB icon
101
BioAtla
BCAB
$5.74M
$1.54M 0.11%
17,482
-10,000
-36% -$839K
ERAS icon
102
Erasca
ERAS
$6.39B
$1.37M 0.1%
502,915
-47,085
-9% -$133K
ENTA icon
103
Enanta Pharmaceuticals
ENTA
$400M
$1.31M 0.09%
126,655
-173,345
-58% -$2.27M
OABI icon
104
OmniAb
OABI
$447M
$1.27M 0.09%
300,000
– –
ATYR
105
aTyr Pharma
ATYR
$50.1M
$1.18M 0.08%
671,134
– –
ATXS
106
DELISTED
Astria Therapeutics
ATXS
$1.1M 0.08%
100,000
– –
PASG icon
107
Passage Bio
PASG
$14.1M
$1.05M 0.08%
75,000
– –
WMT icon
108
Walmart Inc
WMT
$890B
$1.03M 0.07%
12,725
+8,265
+185% +$607K
JPM icon
109
JPMorgan Chase
JPM
$950B
$985K 0.07%
4,673
+2,862
+158% +$603K
MSFT icon
110
Microsoft
MSFT
$3.71T
$968K 0.07%
2,250
+1,436
+176% +$614K
BRK.B icon
111
Berkshire Hathaway Class B
BRK.B
$1.13T
$957K 0.07%
2,079
+1,368
+192% +$605K
HD icon
112
Home Depot
HD
$355B
$954K 0.07%
2,354
+1,675
+247% +$611K
PCRX icon
113
Pacira BioSciences
PCRX
$997M
$921K 0.07%
+61,226
New +$1.05M
VZ icon
114
Verizon
VZ
$196B
$916K 0.07%
20,401
+15,093
+284% +$630K
V icon
115
Visa
V
$677B
$912K 0.07%
3,318
+2,269
+216% +$613K
NXTC icon
116
NextCure
NXTC
$26.7M
$894K 0.06%
54,366
+4,116
+8% +$75.7K
PG icon
117
Procter & Gamble
PG
$339B
$891K 0.06%
5,145
+3,602
+233% +$611K
KO icon
118
Coca-Cola
KO
$375B
$889K 0.06%
12,373
+8,812
+247% +$603K
TXN icon
119
Texas Instruments
TXN
$261B
$868K 0.06%
4,202
+2,998
+249% +$602K
PYPL icon
120
PayPal
PYPL
$50.5B
$866K 0.06%
+11,099
New +$742K
INTC icon
121
Intel
INTC
$513B
$858K 0.06%
36,572
+29,218
+397% +$730K
VTRS icon
122
Viatris
VTRS
$18.9B
$858K 0.06%
73,881
+51,801
+235% +$598K
DIS icon
123
Walt Disney
DIS
$181B
$850K 0.06%
8,834
+6,805
+335% +$626K
NKE icon
124
Nike
NKE
$61.9B
$843K 0.06%
+9,539
New +$748K
UNH icon
125
UnitedHealth
UNH
$370B
$831K 0.06%
+1,422
New +$804K
3 4
5
6 7

Similar funds

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return

Tang Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Tang Capital Management held 162 positions worth $1.4B, up 43% from $982M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Tang Capital Management deployed $336M of net new capital in Q3 2024, opening 35 new positions and adding to 43 existing holdings. Its largest new stake was iTeos Therapeutics: 2,407,800 shares worth $24.6M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Dynavax Technologies, an estimated $6.61M trimmed.

  • Tang Capital Management's largest Q3 2024 buy was iTeos Therapeutics: 2,407,800 shares worth $24.6M.
  • Tang Capital Management added most to Aurinia Pharmaceuticals in Q3 2024, an estimated $27.6M increase.
  • Tang Capital Management's biggest Q3 2024 reduction was Dynavax Technologies, cutting an estimated $6.61M.
  • Tang Capital Management fully exited Eli Lilly in Q3 2024, selling an estimated $24.4M.
  • Tang Capital Management's ten largest holdings make up 36% of its $1.4B portfolio in Q3 2024.
  • Tang Capital Management opened 35 new positions and closed 8 in Q3 2024.
  • Tang Capital Management's portfolio value rose 43% quarter-over-quarter to $1.4B.

Based on Tang Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.